

Matthias P Wymann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8784018/publications.pdf>

Version: 2024-02-01

135
papers

14,933
citations

25014

57
h-index

18633

119
g-index

145
all docs

145
docs citations

145
times ranked

15417
citing authors

#	ARTICLE	IF	CITATIONS
1	Central Role for G Protein-Coupled Phosphoinositide 3-Kinase in Inflammation. <i>Science</i> , 2000, 287, 1049-1053.	6.0	1,187
2	Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine. <i>Molecular Cell</i> , 2000, 6, 909-919.	4.5	1,102
3	Lipid signalling in disease. <i>Nature Reviews Molecular Cell Biology</i> , 2008, 9, 162-176.	16.1	1,091
4	Blockade of PI3K β suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. <i>Nature Medicine</i> , 2005, 11, 936-943.	15.2	711
5	Structure and function of phosphoinositide 3-kinases. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 1998, 1436, 127-150.	1.2	582
6	Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways. <i>Cell</i> , 2002, 110, 737-749.	13.5	545
7	Targeting phosphoinositide 3-kinase—Moving towards therapy. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2008, 1784, 159-185.	1.1	491
8	PI3K β Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects. <i>Cell</i> , 2004, 118, 375-387.	13.5	446
9	Phosphoinositide 3-kinase signalling — which way to target?. <i>Trends in Pharmacological Sciences</i> , 2003, 24, 366-376.	4.0	374
10	Activation of PI3-Kinase Is Required for AMPA Receptor Insertion during LTP of mEPSCs in Cultured Hippocampal Neurons. <i>Neuron</i> , 2003, 38, 611-624.	3.8	317
11	Phosphoinositide 3-Kinase β Is an Essential Amplifier of Mast Cell Function. <i>Immunity</i> , 2002, 16, 441-451.	6.6	292
12	Bifurcation of Lipid and Protein Kinase Signals of PI3K to the Protein Kinases PKB and MAPK. , 1998, 282, 293-296.		288
13	Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. <i>Blood</i> , 2005, 106, 1432-1440.	0.6	274
14	PI(3)K β has an important context-dependent role in neutrophil chemokinesis. <i>Nature Cell Biology</i> , 2007, 9, 86-91.	4.6	233
15	Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase, Rho, and Rac-dependent signaling pathways. <i>FASEB Journal</i> , 2000, 14, 2329-2338.	0.2	230
16	Phosphoinositide 3-Kinase p110 β Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development. <i>Science Signaling</i> , 2008, 1, ra3.	1.6	219
17	Wortmannin binds specifically to 1-phosphatidylinositol 3-kinase while inhibiting guanine nucleotide-binding protein-coupled receptor signaling in neutrophil leukocytes.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 4960-4964.	3.3	201
18	Resistance to thromboembolism in PI3K β -deficient mice. <i>FASEB Journal</i> , 2001, 15, 2019-2021.	0.2	201

#	ARTICLE	IF	CITATIONS
19	Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. <i>Current Opinion in Cell Biology</i> , 2005, 17, 141-149.	2.6	198
20	Turning on the respiratory burst. <i>Trends in Biochemical Sciences</i> , 1990, 15, 69-72.	3.7	197
21	Living with Lethal PIP3 Levels: Viability of Flies Lacking PTEN Restored by a PH Domain Mutation in Akt/PKB. <i>Science</i> , 2002, 295, 2088-2091.	6.0	190
22	Integrating Cardiac PIP3 and cAMP Signaling through a PKA Anchoring Function of p110 β . <i>Molecular Cell</i> , 2011, 42, 84-95.	4.5	174
23	The Forkhead Transcription Factor FOXO3a Increases Phosphoinositide-3 Kinase/Akt Activity in Drug-Resistant Leukemic Cells through Induction of PIK3CA Expression. <i>Molecular and Cellular Biology</i> , 2008, 28, 5886-5898.	1.1	150
24	Defective dendritic cell migration and activation of adaptive immunity in PI3K δ -deficient mice. <i>EMBO Journal</i> , 2004, 23, 3505-3515.	3.5	146
25	Chemiluminescence detection of H2O2 produced by human neutrophils during the respiratory burst. <i>Analytical Biochemistry</i> , 1987, 165, 371-378.	1.1	145
26	A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphate-mediated egress. <i>Journal of Experimental Medicine</i> , 2007, 204, 497-510.	4.2	144
27	Cutting Edge: T Cell Development Requires the Combined Activities of the p110 β and p110 δ Catalytic Isoforms of Phosphatidylinositol 3-Kinase. <i>Journal of Immunology</i> , 2005, 175, 2783-2787.	0.4	142
28	The <i>Drosophila</i> insulin/IGF receptor controls growth and size by modulating PtdIns(3) levels. <i>Development (Cambridge)</i> , 2002, 129, 4103-4109.	1.2	142
29	Genetic and Pharmacological Targeting of Phosphoinositide 3-Kinase- β Reduces Atherosclerosis and Favors Plaque Stability by Modulating Inflammatory Processes. <i>Circulation</i> , 2008, 117, 1310-1317.	1.6	131
30	The Ras/Rac1/Cdc42/SEK/JNK/c-Jun Cascade Is a Key Pathway by Which Agonists Stimulate DNA Synthesis in Primary Cultures of Rat Hepatocytes. <i>Molecular Biology of the Cell</i> , 1998, 9, 561-573.	0.9	127
31	Phosphoinositide 3-kinase β : a key modulator in inflammation and allergy. <i>Biochemical Society Transactions</i> , 2003, 31, 275-280.	1.6	125
32	Loss of phosphatase activity in myotubularin-related protein 2 is associated with Charcot-Marie-Tooth disease type 4B1. <i>Human Molecular Genetics</i> , 2002, 11, 1569-1579.	1.4	124
33	Lipids on the move: phosphoinositide 3-kinases in leukocyte function. <i>Trends in Immunology</i> , 2000, 21, 260-264.	7.5	122
34	Inactivation of PI3K δ and PI3K γ distorts T-cell development and causes multiple organ inflammation. <i>Blood</i> , 2007, 110, 2940-2947.	0.6	113
35	5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7524-7538.	2.9	109
36	Shape changes, exocytosis, and cytosolic free calcium changes in stimulated human eosinophils.. <i>Journal of Clinical Investigation</i> , 1991, 87, 2012-2017.	3.9	106

#	ARTICLE	IF	CITATIONS
37	Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors. <i>Molecular Cancer Research</i> , 2009, 7, 601-613.	1.5	105
38	Mal connects TLR2 to PI3Kinase activation and phagocyte polarization. <i>EMBO Journal</i> , 2009, 28, 2018-2027.	3.5	103
39	Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase β: structure-activity analysis and interactions with wortmannin. <i>Biochemical Journal</i> , 1997, 324, 489-495.	1.7	100
40	The direct effect of leptin on skeletal muscle thermogenesis is mediated by substrate cycling between de novo lipogenesis and lipid oxidation. <i>FEBS Letters</i> , 2004, 577, 539-544.	1.3	95
41	Requirement for PI 3-kinase β in macrophage migration to MCP-1 and CSF-1. <i>Experimental Cell Research</i> , 2003, 290, 120-131.	1.2	94
42	A Selective Role for Phosphatidylinositol 3,4,5-Trisphosphate in the Gi-dependent Activation of Platelet Rap1B. <i>Journal of Biological Chemistry</i> , 2003, 278, 131-138.	1.6	92
43	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 120-129.	3.2	92
44	Elastin-derived peptides potentiate atherosclerosis through the immune Neu1-PI3K β pathway. <i>Cardiovascular Research</i> , 2014, 102, 118-127.	1.8	91
45	Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. <i>Nature Communications</i> , 2017, 8, 14683.	5.8	88
46	Activation Loop Sequences Confer Substrate Specificity to Phosphoinositide 3-Kinase β (PI3K β). <i>Journal of Biological Chemistry</i> , 2001, 276, 21544-21554.	1.6	86
47	Phosphoinositide 3-kinase β participates in T cell receptor-induced T cell activation. <i>Journal of Experimental Medicine</i> , 2007, 204, 2977-2987.	4.2	86
48	Ras is an indispensable coregulator of the class I β phosphoinositide 3-kinase p87/p110 β . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20312-20317.	3.3	84
49	Membrane transport in <i>Caenorhabditis elegans</i> : an essential role for VPS34 at the nuclear membrane. <i>EMBO Journal</i> , 2002, 21, 1673-1683.	3.5	80
50	PI3K β Adaptor Subunits Define Coupling to Degranulation and Cell Motility by Distinct PtdIns(3,4,5)P ₃ Pools in Mast Cells. <i>Science Signaling</i> , 2009, 2, ra27.	1.6	80
51	Phosphatidylinositol 3-Kinase Regulates the CD4/CD8 T Cell Differentiation Ratio. <i>Journal of Immunology</i> , 2003, 170, 4475-4482.	0.4	79
52	Class IB-Phosphatidylinositol 3-Kinase (PI3K) Deficiency Ameliorates IA-PI3K-Induced Systemic Lupus but Not T Cell Invasion. <i>Journal of Immunology</i> , 2006, 176, 589-593.	0.4	78
53	The onset of the respiratory burst in human neutrophils. Real-time studies of H ₂ O ₂ formation reveal a rapid agonist-induced transduction process. <i>Journal of Biological Chemistry</i> , 1987, 262, 12048-53.	1.6	76
54	Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. <i>European Journal of Immunology</i> , 2005, 35, 1283-1291.	1.6	70

#	ARTICLE	IF	CITATIONS
55	The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy. <i>Neuropharmacology</i> , 2018, 140, 107-120.	2.0	64
56	Protein adsorption on topographically nanostructured titanium. <i>Surface Science</i> , 2001, 474, L180-L184.	0.8	62
57	Lack of phosphoinositide 3-kinase- β attenuates ventilator-induced lung injury*. <i>Critical Care Medicine</i> , 2006, 34, 134-141.	0.4	62
58	PKC β Phosphorylates PI3K β to Activate It and Release It from GPCR Control. <i>PLoS Biology</i> , 2013, 11, e1001587.	2.6	62
59	Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders. <i>Journal of Medicinal Chemistry</i> . 2018. 61. 10084-10105.	2.9	62
60	Leukocyte transmigration is modulated by chemokine-mediated PI3K β -dependent phosphorylation of vimentin. <i>European Journal of Immunology</i> , 2009, 39, 1136-1146.	1.6	59
61	Essential Role of the p110 β Subunit of Phosphoinositide 3-OH Kinase in Male Fertility. <i>Molecular Biology of the Cell</i> , 2010, 21, 704-711.	0.9	58
62	Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase β . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 14354-14359.	3.3	57
63	PI3K β within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, E854-63.	3.3	55
64	Plasmin Inhibitors Prevent Leukocyte Accumulation and Remodeling Events in the Postischemic Microvasculature. <i>PLoS ONE</i> , 2011, 6, e17229.	1.1	54
65	C-C motif chemokine CCL3 and canonical neutrophil attractants promote neutrophil extravasation through common and distinct mechanisms. <i>Blood</i> , 2012, 120, 880-890.	0.6	52
66	Cell-Permeant and Photocleavable Chemical Inducer of Dimerization. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 4717-4720.	7.2	51
67	Human PI3K β deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology. <i>Nature Communications</i> , 2019, 10, 4364.	5.8	51
68	Respiratory burst oscillations in human neutrophils and their correlation with fluctuations in apparent cell shape. <i>Journal of Biological Chemistry</i> , 1989, 264, 15829-34.	1.6	51
69	Ablation of Phosphoinositide 3-Kinase- β Reduces the Severity of Acute Pancreatitis. <i>American Journal of Pathology</i> , 2004, 165, 2003-2011.	1.9	49
70	Chemical Development of Intracellular Protein Heterodimerizers. <i>Chemistry and Biology</i> , 2013, 20, 549-557.	6.2	49
71	N-formyl peptide receptors in human neutrophils display distinct membrane distribution and lateral mobility when labeled with agonist and antagonist.. <i>Journal of Cell Biology</i> , 1993, 121, 1281-1289.	2.3	46
72	(<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6241-6261.	2.9	45

#	ARTICLE	IF	CITATIONS
73	GABAA receptor-associated phosphoinositide 3-kinase is required for insulin-induced recruitment of postsynaptic GABAA receptors. <i>Neuropharmacology</i> , 2007, 52, 146-155.	2.0	44
74	Increased breakdown of phosphatidylinositol 4,5-bisphosphate is not an initiating factor for actin assembly in human neutrophils. <i>Journal of Biological Chemistry</i> , 1988, 263, 17385-9.	1.6	44
75	New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease. <i>Haematologica</i> , 2019, 104, e256-e259.	1.7	43
76	A class of highly selective inhibitors bind to an active state of PI3K \hat{I}^3 . <i>Nature Chemical Biology</i> , 2019, 15, 348-357.	3.9	42
77	Fluid-Phase Pinocytosis of Native Low Density Lipoprotein Promotes Murine M-CSF Differentiated Macrophage Foam Cell Formation. <i>PLoS ONE</i> , 2013, 8, e58054.	1.1	42
78	Weakening link to colorectal cancer?. <i>Nature</i> , 2001, 413, 796-796.	13.7	41
79	Murine bone marrow-derived macrophages differentiated with GM-CSF become foam cells by PI3K \hat{I}^3 -dependent fluid-phase pinocytosis of native LDL. <i>Journal of Lipid Research</i> , 2012, 53, 34-42.	2.0	39
80	The Chemical Biology of Phosphoinositide 3-kinases. <i>ChemBioChem</i> , 2012, 13, 2022-2035.	1.3	35
81	Essential role of phosphoinositide 3-kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation. <i>Immunology</i> , 2009, 126, 413-422.	2.0	33
82	Phosphoinositide 3-kinase \hat{I}^3 mediates microglial phagocytosis via lipid kinase-independent control of cAMP. <i>Neuroscience</i> , 2013, 233, 44-53.	1.1	30
83	Key role of PI3K \hat{I}^3 in monocyte chemotactic protein \hat{I}^1 -mediated amplification of PDGF \hat{I}^{α} -induced aortic smooth muscle cell migration. <i>British Journal of Pharmacology</i> , 2012, 166, 1643-1653.	2.7	29
84	Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 959-968.	1.5	29
85	PI3K \hat{I}^3 activity in leukocytes promotes adipose tissue inflammation and early-onset insulin resistance during obesity. <i>Science Signaling</i> , 2017, 10, .	1.6	29
86	Targeting PI3K \hat{I}^3 activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 response. <i>Journal of Experimental Medicine</i> , 2014, 211, 1779-1792.	4.2	28
87	Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl \hat{I}^{α} -Pyrimidine Moiety. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1473-1479.	1.3	28
88	Disease-related mutations in PI3K \hat{I}^3 disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors. <i>ELife</i> , 2021, 10, .	2.8	28
89	Oscillatory motion in human neutrophils responding to chemotactic stimuli. <i>Biochemical and Biophysical Research Communications</i> , 1987, 147, 361-368.	1.0	27
90	Covalent Proximity Scanning of a Distal Cysteine to Target PI3K \hat{I}^3 . <i>Journal of the American Chemical Society</i> , 2022, 144, 6326-6342.	6.6	27

#	ARTICLE	IF	CITATIONS
91	Susi, a Negative Regulator of Drosophila PI3-Kinase. <i>Developmental Cell</i> , 2005, 8, 817-827.	3.1	24
92	A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8609-8630.	2.9	24
93	Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. <i>Neuropharmacology</i> , 2020, 180, 108297.	2.0	23
94	The role of PI3K \hat{I}^3 in the immune system: new insights and translational implications. <i>Nature Reviews Immunology</i> , 2022, 22, 687-700.	10.6	22
95	Inhibition of phosphoinositide 3-kinase \hat{I}^3 attenuates inflammation, obesity, and cardiovascular risk factors. <i>Annals of the New York Academy of Sciences</i> , 2013, 1280, 44-47.	1.8	21
96	Phosphoinositide 3-kinase \hat{I}^3 -deficient hearts are protected from the PAF-dependent depression of cardiac contractility. <i>Cardiovascular Research</i> , 2003, 60, 242-249.	1.8	20
97	Phosphoinositide 3-kinase \hat{I}^3 controls autonomic regulation of the mouse heart through Gi-independent downregulation of cAMP level. <i>FEBS Letters</i> , 2005, 579, 133-140.	1.3	20
98	Microquantification of Cellular and in Vitro F-Actin by Rhodamine Phalloidin Fluorescence Enhancement. <i>Analytical Biochemistry</i> , 1998, 264, 185-190.	1.1	19
99	Targeting PI3K in neuroblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1881-1890.	1.2	19
100	PI3K p110 \hat{I}^3 Deletion Attenuates Murine Atherosclerosis by Reducing Macrophage Proliferation but Not Polarization or Apoptosis in Lesions. <i>PLoS ONE</i> , 2013, 8, e72674.	1.1	17
101	4-(Difluoromethyl)-5-(4-((3 <i>R</i>)-5 <i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13595-13617.	2.9	17
102	Analysis of the murine phosphoinositide 3-kinase \hat{I}^3 gene. <i>Gene</i> , 2000, 256, 69-81.	1.0	16
103	Genetic ablation of PI3K \hat{I}^3 results in defective IL-17RA signalling in T lymphocytes and increased IL-17 levels. <i>European Journal of Immunology</i> , 2012, 42, 3394-3404.	1.6	14
104	The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. <i>Cancers</i> , 2019, 11, 775.	1.7	14
105	Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD. <i>Neuropharmacology</i> , 2020, 162, 107812.	2.0	12
106	Chemical and Structural Strategies to Selectively Target mTOR Kinase. <i>ChemMedChem</i> , 2021, 16, 2744-2759.	1.6	12
107	The ATP-binding site of brain phosphatidylinositol 4-kinase PI4K230 as revealed by 5- \hat{I}^2 -p-fluorosulfonylbenzoyladenine. <i>International Journal of Biochemistry and Cell Biology</i> , 2001, 33, 249-259.	1.2	11
108	PI3K \hat{I}^3 Regulatory Protein p84 Determines Mast Cell Sensitivity to Ras Inhibition—Moving Towards Cell Specific PI3K Targeting?. <i>Frontiers in Immunology</i> , 2020, 11, 585070.	2.2	10

#	ARTICLE	IF	CITATIONS
109	PI3Ksâ€™ Drug Targets in Inflammation and Cancer. <i>Sub-Cellular Biochemistry</i> , 2012, 58, 111-181.	1.0	9
110	Scalable, Economical, and Practical Synthesis of 4-(Difluoromethyl)pyridin-2-amine, a Key Intermediate for Lipid Kinase Inhibitors. <i>Organic Process Research and Development</i> , 2019, 23, 2416-2424.	1.3	8
111	Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted bloodâ€™brain barrier permeability. <i>RSC Medicinal Chemistry</i> , 2021, 12, 579-583.	1.7	6
112	Phosphoinositide 3-kinase gamma; participates in T cell receptorâ€™induced T cell activation.. <i>FASEB Journal</i> , 2008, 22, 1064.12.	0.2	4
113	Neutral not a loss: phosphoinositides beyond the head group. <i>Nature Methods</i> , 2011, 8, 219-220.	9.0	3
114	Abstract 2664: PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor. <i>Cancer Research</i> , 2015, 75, 2664-2664.	0.4	3
115	Abstract 4514: PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability. <i>Cancer Research</i> , 2015, 75, 4514-4514.	0.4	3
116	Targeting Phosphoinositide 3-Kinase â€™ Five Decades of Chemical Space Exploration. <i>Chimia</i> , 2021, 75, 1037.	0.3	3
117	Luminal decoration of blood vessels by activated perivascular mast cells in allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 510-520.	2.7	2
118	Suppression of caspase 8 activity by a coronin 1â€™PI3KÎ’ pathway promotes T cell survival independently of TCR and IL-7 signaling. <i>Science Signaling</i> , 2021, 14, eabj0057.	1.6	2
119	Phosphoinositide 3-kinase Î³ mediates Jun kinase activation via its lipid-kinase activity. <i>Advances in Enzyme Regulation</i> , 2004, 44, 299-308.	2.9	1
120	Membrane dynamics in physiology and disease. <i>FEBS Journal</i> , 2013, 280, 2729-2729.	2.2	1
121	Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas. , 2015, , .		1
122	Abstract 671: BKM120-mediated G2 arrest: Structural and functional segregation of off-target action and PI3K inhibition. , 2015, , .		1
123	Abstract 140: Discovery and biological evaluation of PQR530, a highly potent dual pan-PI3K/mTORC1/2 inhibitor. , 2017, , .		1
124	Abstract 159: Pharmacological characterization of the selective, orally bioavailable, potent dual PI3K/mTORC1/2 inhibitor PQR530. , 2017, , .		1
125	Phosphoinositide 3-kinase Signalling â€™ no lipids. <i>Biochemical Society Transactions</i> , 1999, 27, A74-A74.	1.6	0
126	Mast cell degranulation requires activation of PI3K Î³ by PKC Î². <i>Cytokine</i> , 2009, 48, 41.	1.4	0

#	ARTICLE	IF	CITATIONS
127	0377 : Phosphoinositide 3-kinase gamma: a potential clinical target in the prevention of vascular damages inuced by arterial injury. Archives of Cardiovascular Diseases Supplements, 2015, 7, 134.	0.0	0
128	Vascular Remodeling in Cardiovascular Disease231Absence of PI3Kg leads to increased reendothelialization in mice through modulation of IP-10 secretion.232DPP4 inhibition mediates vascular protection in acute and chronic vascular injury233Effects of transforming growth factor beta signalling on smooth muscle cell phenotype in the angiotensin II-induced abdominal aortic aneurysm model. Cardiovascular Research, 2016, 111, S44-S44.	1.8	0
129	Phosphoinositide 3-kinase Î³ participates in T cell receptor-induced T cell activation. Journal of Cell Biology, 2007, 179, i9-i9.	2.3	0
130	Abstract 393A: Pharmacological characterization of the selective, orally bioavailable, potent mTORC1/2 inhibitor PQR620. , 2016, , .		0
131	Abstract 1364: Novel 4-(pyrimidin-2-yl)morpholines targeting the colchicine-binding site of tubulin. , 2016, , .		0
132	Abstract 1336: Structure-activity relationship studies, synthesis, and biological evaluation of PQR620, a highly potent and selective mTORC1/2 inhibitor. , 2016, , .		0
133	Abstract 153: Tricyclic fused pyrimidinopyrrolo-oxazines reveal conformational preferences of morpholine for PI3K hinge region binding. , 2017, , .		0
134	Central role for phosphoinositide-3-kinase gamma/delta dependent signalling in eosinophilic pulmonary inflammation driven by innate lymphoid cells. , 2017, , .		0
135	Abstract 665: Discovery and preclinical characterization of PQR626: A potent, orally available, and brain-penetrant mTOR inhibitor for the treatment of tuberous sclerosis complex. , 2020, , .		0